Treace Medical Concepts, Inc. has recently announced a board chair transition, with John T. Treace being appointed as the new chairman of the board, effective immediately following the 2025 annual meeting of stockholders. This transition comes as James T. Treace, the current chairman, has notified the board of his intention to retire from the board at the end of his current term.
John T. Treace, who is currently the chief executive officer and founder of Treace, will continue to serve as CEO while taking on the role of chairman. This appointment follows a distinguished career, with Mr. James T. Treace having served as the founder and president of J&A Group, LLC, and in various executive positions at companies such as Xomed Surgical Products, Inc., Trebay Medical Corp., and Concept, Inc.
The announcement also highlighted the company's expanded bunion portfolio and its commitment to delivering additional innovations to address the evolving needs of surgeon customers in 2025 and beyond. As the company looks ahead to the next chapter, the appointment of John T. Treace as chairman is seen as a strategic move to guide the company during this exciting phase.
Richard W. Mott, the lead independent director of Treace, expressed gratitude for James T. Treace's dedication and service, while congratulating John T. Treace on his appointment as chairman. Mott emphasized John's integral role in the company's strategic evolution and his deep understanding of the business, as well as his commitment to innovation, continuous improvement, and success.
The transition in leadership at Treace Medical Concepts, Inc. signals a pivotal moment for the company as it strives to create exceptional value for its customers, stockholders, and employees under the guidance of its new chairman. Today the company's shares have moved -2.8% to a price of $7.53. For more information, read the company's full 8-K submission here.
